Cargando…

Serum lipid profiles and aggressive prostate cancer

Detalles Bibliográficos
Autores principales:	Li, Yanjing, Liang, Chaozhao, Huang, Jiaoti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Invited Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650480/ https://www.ncbi.nlm.nih.gov/pubmed/25475667 http://dx.doi.org/10.4103/1008-682X.143308

Ejemplares similares

Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression
por: Feng, Ninghan, et al.
Publicado: (2019)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer
por: Le, Jesse D, et al.
Publicado: (2014)

Commentary on “Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies)”
por: Koochekpour, Shahriar
Publicado: (2015)

The association between serum lipid profile and the prostate cancer risk and aggressiveness
por: Suh, Jungyo, et al.
Publicado: (2023)

Separate Chinese lines for prostate cancer?
por: von Eyben, Finn Edler
Publicado: (2019)

Impact of IL-23 in prostate cancer
por: Mirlekar, Bhalchandra
Publicado: (2021)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Isolated native renal hydatidosis in a renal transplant patient: The case for an aggressive approach
por: Mubarak, Muhammed
Publicado: (2018)

Risk-prediction tools in prostate cancer: the challenge of tailoring
por: Morlacco, Alessandro, et al.
Publicado: (2016)

New models for defining prostate cancer biology and patient prognosis
por: Brundage, James, et al.
Publicado: (2021)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

Findings from a prostate cancer screening program in a Japanese population
por: Ranasinghe, Weranja K B, et al.
Publicado: (2014)

Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
por: Xu, Lingfan, et al.
Publicado: (2019)

Speckle-type POZ protein mutations in prostate cancer: a new part of the mosaic
por: Stoehr, Robert
Publicado: (2015)

Sexual dysfunction and prostate cancer risk: one more piece of a complex puzzle
por: Capogrosso, Paolo, et al.
Publicado: (2017)

Bacteria and the prostate: infertility versus symptoms
por: Pontari, Michel A
Publicado: (2014)

Extended lymph node dissection for intermediate and high-risk prostate cancer: do we have all the evidence?
por: Ghazi, Ahmed
Publicado: (2015)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

Models for Predicting Drug Absorption From Oral Lipid-Based Formulations
por: Alskär, Linda C., et al.
Publicado: (2015)

Re: Fasting times in serum PSA assay
por: Lau, Cheryl K, et al.
Publicado: (2014)

Commentary on “Clinical implications of endogenous testosterone density in prostate cancer progression in patients with favorable low and intermediate risk treated with radical prostatectomy”
por: Busetto, Gian Maria, et al.
Publicado: (2023)

Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients
por: Mone, Pasquale, et al.
Publicado: (2022)

Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods
por: Moyad, Mark A
Publicado: (2015)

Blood-based bioenergetic profiling: A readout of systemic bioenergetic capacity that is related to differences in body composition()
por: Molina, Anthony J.A.
Publicado: (2017)

Rewired lipid metabolism as an actionable vulnerability of aggressive colorectal carcinoma
por: Capece, Daria, et al.
Publicado: (2022)

Implications of local failure on overall prognosis in aggressive prostate cancer
por: Mula-Hussain, Layth, et al.
Publicado: (2020)

Aggressive corticotroph tumors and carcinomas
por: Lasolle, Hélène, et al.
Publicado: (2022)

Azoospermia and the cancer patient: are there any options?
por: Kovac, Jason R, et al.
Publicado: (2016)

Role of frailty assessment in selection for cancer surgery
por: Allum, William H
Publicado: (2022)

Endo180 at the cutting edge of bone cancer treatment and beyond
por: Sturge, Justin
Publicado: (2016)

BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people
por: Zhao, Ruizhe, et al.
Publicado: (2017)

Analysis of Cyclin D1 in Breast Cancer: A Call to Arms
por: Tobin, Nicholas P., et al.
Publicado: (2012)

Cancer genetics program: Follow‐up on clinical genetics and genomic medicine in Qatar
por: Al‐Bader, Salha Bujassoum, et al.
Publicado: (2018)

p27(Kip1) – p(RhoB)lematic in lung cancer
por: Podmirseg, Silvio R, et al.
Publicado: (2019)

Copy‐number intratumor heterogeneity as high‐risk feature of stage II colon cancer(†)
por: van den Bosch, Tom, et al.
Publicado: (2022)

Redressing breast cancer screening disparities during the COVID-19 pandemic: Turning crisis into opportunity
por: Fieber, Jennifer H., et al.
Publicado: (2022)

Invited Commentary: The Clinical Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid Cancer
por: Barczyński, Marcin
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a169ji409v6urlftnsdmt5i2mn